(Press-News.org) ROCKVILLE, Md.— New findings show that the medication known as Wegovy® (semaglutide) can reduce existing heart disease in patients with obesity by 20%, according to a study co-authored by past presidents of The Obesity Society (TOS) and published in The New England Journal of Medicine.
"The SELECT trial is the first study showing that prescription of an anti-obesity medication in people with overweight or obesity and existing cardiovascular disease can be life-saving,” said co-author and TOS Past President Robert F. Kushner, MD, FTOS, professor, Departments of Medicine and Medical Education, Northwestern University Feinberg School of Medicine, Chicago, Ill.
Kushner added that the impact of this observation was shared by attendees at the opening session of the American Heart Association’s Scientific Sessions, where the results were presented on Nov. 11, 2023, in Philadelphia, Pa.
TOS Past President Caroline M. Apovian, MD, FTOS, served as chair of session discussing the study’s results. She observed that the enthusiasm in the room as the positive cardiovascular reduction results in this cardiovascular outcomes trial of semaglutide in obesity were unveiled “leads us to great hope that cardiologists followed by primary care providers will prescribe glucagon-like peptide-1 receptor agonists and other Nutrient Stimulated Hormone Therapies to all patients with obesity,” she said.
Apovian added “this is the only way to ensure that third-party payors will abandon their short term view of health care cost reduction and pay the costs of these medications to allow 42% of Americans with obesity to live healthier and longer lives.” Apovian is professor at Harvard Medical School and co-director of the Center for Weight Management and Wellness at Brigham and Women’s Hospital, Boston, Mass.
Whether semaglutide can reduce cardiovascular risk associated with overweight and obesity in the absence of diabetes has been unknown. In a multi-center, double-blind, randomized, placebo-controlled, event-driven superiority trial, patients 45-years of age or older with pre-existing cardiovascular disease and a body mass index of 27 or over with no history of diabetes were enrolled in the study.
Patients were randomly assigned in a 1:1 ratio to receive once-weekly subcutaneous semaglutide at a dose of 2.4 mg or placebo. The primary cardiovascular end point was a composite of death from cardiovascular causes, non-fatal myocardial infarction or non-fatal stroke in a time-to-first-event analysis. Safety was also assessed.
Study co-author and TOS Past President Donna Ryan, MD, FTOS, professor emerita of the Pennington Biomedical Research Center in Baton Rouge, La., said, “The overall message was one of consistency—reduction in major adverse cardiovascular events and other hard outcomes as well as benefits for all sub-groups studied.”
She added, “The efficacy profile continued to all the relevant cardiometabolic intermediate end points and the safety profile was reassuring. I felt that the audience had confidence in the results because of the precision with which the study was executed. There were 99% of patients whose status was known at the study’s end. All this good news has been a long time coming—everyone in The Obesity Society community deserves accolades for staying attentive to what obesity really is: a serious chronic disease of excess abnormal body fat. It’s a win, but it is more important than ever that TOS members continue the basic, clinical and population research so needed to conquer this disease.”
Other authors of the study include A. Michael Lincoff, Kirstine Brown‑Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‑Lindberg, G. Kees Hovingh, Steven E. Kahn, Ildiko Lingvay, Tugce K. Oral, Marie M. Michelsen, Jorge Plutzky and Christoffer W. Tornøe.
To view a copy of the study titled “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes,” visit The New England Journal of Medicine website.
# # #
The Obesity Society (TOS) is the leading organization of scientists and health professionals devoted to understanding and reversing the epidemic of obesity and its adverse health, economic and societal effects. Combining the perspective of researchers, clinicians, policymakers and patients, TOS promotes innovative research, education and evidence-based clinical care to improve the health and well-being of all people with obesity. For more information, visit www.obesity.org.
END
At this year’s American College of Rheumatology (ACR) annual meeting, Hospital for Special Surgery (HSS) presented a number of important studies focused on reproductive health for patients with systemic lupus erythematosus, rheumatoid arthritis, and other rheumatic diseases, including issues related to fertility, sexual function, use of contraception and HPV vaccination.
What follows are some highlights from the meeting:
Association of Menstrual Cycles and Disease Flare Activity in Women with Systemic Lupus Erythematosus and Rheumatoid Arthritis
In this study, researchers surveyed female rheumatology ...
A new study out this week in the journal Social Science and Medicine proposes that social, gendered variables may better explain observed sex disparities in adverse drug events than sex-based biology.
Adverse drug events refer to harmful side effects resulting from the use of a drug. A 1.5-2 times higher rate of adverse drug events in women compared to men has long been observed, and addressing this disparity has been an enduring priority of women’s health advocates, medical researchers, and institutions such as the National Institutes of Health.
Advocates ...
November 14, 2023, Mountain View, CA - Dr. Franck Marchis, a senior planetary astronomer at the SETI Institute, was appointed as a 2023 Fellow by the California Academy of Sciences (Cal Academy). Recognized for his exceptional contributions to the natural sciences, Marchis joins a distinguished group of scientists, including other notable SETI Institute Fellows of Cal Academy, such as Dr. Jill Tarter, Dr. Nathalie Cabrol, Dr. Seth Shostak, and Trustee Andrew Fraknoi.
“As an astronomer, I am constantly amazed by the vastness and complexity of the universe,” ...
HOUSTON ― The James P. Allison Institute at The University of Texas MD Anderson Cancer Center hosted its inaugural scientific symposium on Nov. 10 at the TMC3 Collaborative Building in the Texas Medical Center’s Helix Park. The event brought together more than 400 leading scientists, including three Nobel laureates, from multiple disciplines to share groundbreaking immunotherapy and immunobiology research.
“Our inaugural symposium is an important milestone representing significant progress for the Allison Institute since we launched last year, and we’re energized by the exceptional science shared by our members and colleagues,” ...
The team that built Frontier set out to break the exascale barrier, but the supercomputer’s record-breaking didn’t stop there.
“The exascale number marks a major milestone itself, but it also marks the beginning of a new chapter in high-speed computing,” said Feiyi Wang, an Oak Ridge National Laboratory computer scientist who leads research into artificial intelligence and analytics. “We don’t have to wait for the next generation of computing anymore. We can have it here today.”
Frontier claimed the title of fastest computer in the world by running at ...
COLUMBUS, Ohio – For the first time, teachers in a nationwide study have told researchers what strategies they think work best to deal with student violence against educators.
Teachers rated suspending or expelling students as the least effective way of addressing violence, despite the popularity of “zero tolerance” policies in many school districts.
Instead, teachers rated prevention policies, such as counseling for troubled students and improving school climate, as the best strategy for dealing with violence.
“Teachers ...
In the area of cloud computing, i.e. on-demand access to IT resources via the internet, so-called trusted execution environments (TEEs) play a major role. They are designed to ensure that the data on the virtual work environments (virtual machines) is secure and cannot be manipulated or stolen. Researchers at the CISPA Helmholtz Centre for Information Security and Graz University of Technology (TU Graz) have now discovered a security vulnerability in AMD processors that allows attackers to penetrate virtual work environments based on the trusted computing technologies AMD SEV-ES and AMD SEV-SNP. This is achieved by resetting data changes in the buffer memory (cache), which gives ...
Philadelphia, November 14, 2023 – Cooking and recipe demonstrations encourage healthy eating and adoption of unfamiliar foods by class participants. The research brief shared in the Journal of Nutrition Education and Behavior, published by Elsevier, demonstrates that valuable input by peer educators can be obtained through a hybrid home-use testing method.
The process of recipe development involves sensory evaluation about the appearance, aroma, taste, texture, and flavor of the food. Although a controlled laboratory setting is the gold standard for evaluation because of consistent preparation and presentation of food, bringing peer educators to a ...
New Rochelle, NY, November 13, 2023—A new review article in the peer-reviewed journal Human Gene Therapy summarizes the significant milestones in the development of gene therapy medicinal products that have facilitated the treatment of a significant number of rare diseases. The article also describes the challenges in the progress of gene therapy for rare diseases. Click here to read the article now.
Juan Bueren, from Centro de Investigaciones Energéticas Medioambientalies y Tecnológicas (CIEMAT), ...
HIV pre-exposure prophylaxis (PrEP), a daily dose of two medications meant to prevent HIV infection in high-risk people, has changed public health dramatically in recent years. Yet, adolescents and young adults, one high-risk group, have shown slower uptake in using this prevention method.
Despite accounting for around 20 percent of new HIV infections, adolescents and young adults between the ages of 13 and 24 are still largely not being prescribed PrEP. Research has described physician intentions to prescribe PrEP to at-risk young people, but no studies until now have focused on factors that may affect actual prescribing of this evidence-based ...
